Clinical trials: Effect of Drugs
Healthy
A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants
The purpose of this study is to determine the effect of quinidine on the levels of orforglipron in the blood stream and how long it takes the body to eliminate it, when administered orally in healthy participants.
- Trial name
- NCT06704763
- Testing
- Orforglipron, Midazolam, Quinidine
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Leishmaniasis; American, Cutaneous, Drug Side Effect
Phase 2 Trial to Evaluate 18-Methoxycoronaridine Efficacy, Safety and Tolerability in Cutaneous Leishmaniasis Patients
It is a randomized phase II clinical study, unicentre aimed to evaluate the tolerability, safety and efficacy of 18-Methoxyoronaridine as a candidate of tegumentary leishmaniasis treatment.
- Trial name
- NCT03084952
- Testing
- 18-Methoxycoronaridine, Glucantime
- Volunteers
- 52 people
- Sponsor
- Infan Industria Quimica Farmaceutica Nacional
Healthy, Food-drug Interaction
Relacorilant Food Effect Study in Healthy Subjects
This is an open-label, randomized, single-dose, 3-period crossover, Williams' design, food-interaction (fasted and fed arms) study conducted in healthy subjects.
- Trial name
- NCT03442621
- Testing
- Relacorilant Fasted, Relacorilant with a high fat breakfast, Relacorilant with a moderate breakfast
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Corcept Therapeutics
Invasive Aspergillosis
Drug/Drug Interactions With F901318
Study of interactions between F901318 and multiple doses of posaconazole and pantoprazole and single doses of cyclosporine A and tacrolimus in healthy subjects.
- Trial name
- NCT03095547
- Testing
- cyclosporine A, Posaconazole, Pantoprazole
- Volunteers
- healthy volunteers welcome
- Sponsor
- F2G Ltd
Pain
A Methodology Study Of Brain Imaging Of Pain-Killers In Post-Traumatic Neuropathic Pain Patients
This study is a methodology study designed to discover whether a brain imaging technology is a better way of compare the relative sensitivities of fMRI and subjective psychometric assessments of pain to multiple doses of…
- Trial name
- NCT00610155
- Testing
- Pregabalin, Tramadol SR
- Where
- 2 sites in United Kingdom
- Volunteers
- 18 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Advanced Solid Tumors
Study of MLN8237 in Participants With Advanced Solid Tumors
The purposes of this study were to estimate the relative (Rel) bioavailability (BA) of an oral solution (OS) formulation of alisertib in reference to a powder-in-capsule (PIC) formulation, to characterize the effect of food on…
- Trial name
- NCT00962091
- Testing
- Alisertib
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
All Malignancies, Advanced Malignancies
Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels
The participants of this study will have advanced malignancies (also known as advanced cancer). The main aim of this trial will be to study the blood levels (known as pharmacokinetics) of the tazemtostat (the study drug) when…
- Conditions
- All Malignancies, Advanced Malignancies, Hematologic Malignancy, Solid Tumor
- Trial name
- NCT04537715
- Testing
- Tazemetostat, Itraconazole, Rifampin
- Where
- 10 sites in United States, Spain
- Volunteers
- 42 people
- Sponsor
- Epizyme, Inc.
Type 2 Diabetes
Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
This is a non-inferiority study comparing omarigliptin with sitagliptin in participants with type 2 diabetes mellitus (T2DM) with inadequate glycemic control on metformin therapy.
- Trial name
- NCT01841697
- Testing
- Omarigliptin, Sitagliptin, Open-label Metformin
- Volunteers
- 642 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypertension
H-Type Hypertension Precision Medicine Trial
This is a multicenter, randomized, double-blind, controlled clinical trial. It aims to investigate the effects of different doses of folic acid on lowering homocysteine (Hcy) in patients with hypertension with different genotypes…
- Trial name
- NCT03472508
- Testing
- Folic Acid, Enalapril Maleate and Folic Acid Tablets (Yiye), Enalapril
- Where
- 5 sites in China
- Volunteers
- 3,600 people
- Sponsor
- Shenzhen Ausa Pharmed Co.,Ltd
Healthy
Drug Interaction Study Evaluating the Effect of Rifampin on PK and Safety of PF 04965842.
This is a Phase 1 open label, 2 period, single fixed sequence study designed to evaluate the effect of repeat dose oral rifampin on single dose PF 04965842 PK after a single 200 mg oral dose in healthy subjects.
- Trial name
- NCT03637790
- Testing
- PF-04965842, rifampin
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Volunteers
A Study to Evaluate Drug-Drug Interaction of Larotinib With Itraconazole and Rifampin in Healthy Adult Participants
The purpose of this study is to characterize the effect of rifampin (Part A) and itraconazole(Part B) on the single-dose pharmacokinetics (PK) of Larotinib in healthy adult participants.
- Trial name
- Z650 (NCT05057949)
- Testing
- Larotinib, Rifampin, Itraconazole
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Drug Interaction, Healthy Volunteer
A Study to Examine the Effects of Entinostat on Midazolam in Healthy Adult Subjects
The purpose of this study is to evaluate the effect of Entinostat on the bioavailability of Midazolam. The primary objective is to evaluate the effect of a single oral dose of entinostat on the pharmacokinetics (PK) of a single…
- Trial name
- NCT03187015
- Testing
- Entinostat, Midazolam
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Syndax Pharmaceuticals
ER-Positive HER2-Negative Breast Cancer
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
The study is intended to show superiority of AZD9833 in combination with palbociclib (a CDK4/6 inhibitor) versus anastrozole (an aromatase inhibitor) and palbociclib as the initial treatment of patients with hormone…
- Trial name
- SERENA-4 (NCT04711252)
- Testing
- AZD9833, Anastrozole, Palbociclib
- Where
- 263 sites in United States, Austria and 25 more
- Volunteers
- 1,371 people
- Sponsor
- AstraZeneca
Drug Interactions, Neoplasms
A Cross-over Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics (PK) of GSK525762 in Healthy Female Subjects of Non Child Bearing Potential
This is a Phase I, single center, two-part, randomized, open label, cross-over study. Part 1 of this study will evaluate the PK, safety, and tolerability of GSK525762 when administered alone and when co-administered following…
- Trial name
- NCT02706535
- Testing
- GSK525762 Besylate Tablets, Itraconazole 200 mg, Rifampicin 300 mg
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pharmaceutical Preparations, Health Adult Subjects
Food Effect Study of HSK47388 in Healthy Subjects
This is a Phase 1, open-label, randomized, three-period crossover trial study to evaluate the effect of food and dosing and meal timing intervals on the pharmacokinetics (PK) of HSK46575 in healthy adult participants ,with an…
- Trial name
- NCT07192692
- Testing
- fast, low fat meal, take meal after HSK47388 administration
- Where
- China
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Diabetes Mellitus, Type 2
A Type 2 Diabetes Study of the Longer-Term Glycemic Effect of AVANDAMET vs. Metformin
This study will evaluate the longer-term glycemic effect of two medicines approved for initial treatment of type 2 diabetes. The study consists of a 2 week screening period (2 study visits), followed by an 80 week double-blind…
- Trial name
- NCT00386100
- Testing
- Avandamet 6 mg/1500 mg (ttd), Avandamet 4 mg/1000 mg (ttd), Avandamet 2 mg/500 mg (ttd)
- Where
- 116 sites in United States, Argentina and 7 more
- Volunteers
- 688 people
- Sponsor
- GlaxoSmithKline
Advanced Non-Central Nervous System (CNS) Malignancies
A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies
The purpose of this Phase 1 of the study is to evaluate the effect of food on the pharmacokinetics (PK) of oprozomib, the drug-drug interaction of oprozomib with midazolam, and the safety and tolerability of oprozomib in patients…
- Trial name
- NCT02244112
- Testing
- Oprozomib, Midazolam
- Where
- 7 sites in United States
- Volunteers
- 43 people
- Sponsor
- Amgen
Physiological Effects of Drugs, Neoplasms by Histologic Type
Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies
SHR-1603-I-101 is an single-arm, open-label, dose finding phase I clinical trial of SHR-1603 in subjects with advanced solid tumor or relapsed/refractory malignant lymphoid diseases.
- Conditions
- Physiological Effects of Drugs, Neoplasms by Histologic Type, Lymphoma, Hematologic Neoplasms
- Trial name
- NCT03722186
- Testing
- SHR-1603
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Pharmacokinetics, Healthy
Drug-Drug Interaction Study Between Colchicine and Cyclosporine
Colchicine is a substrate for both cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp). Cyclosporine is a potent inhibitor of both CYP3A4 and P-gp.
- Trial name
- NCT00983931
- Testing
- Colchicine, Cyclosporine
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Mutual Pharmaceutical Company, Inc.
Advanced Solid Tumors, Excluding Breast Cancer
Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors.
This is a multi-center, open-label, single-sequence, crossover, drug-drug interaction (DDI) study to assess the effect of the CYP1A2 inhibitor, fluvoxamine, on the PK of dovitinib in patients with advanced solid tumors, excluding…
- Trial name
- CTKI258A2120 (NCT01700270)
- Testing
- dovitinib (TKI258), fluvoxamine
- Where
- 6 sites in United States, Denmark and 2 more
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.